Therefore, the CD4 receptor, and the entry coreceptors CCR5 and CXCR4 have been considered attractive targets for shRNA therapy to prevent the initiation of HIV-1 infection and inhibit the fusion of the host cell membrane with HIV-1 (see Figure 2B) (28, 39). The gene discussed is CD4; the disease is HIV-1 infection.